Vanda Rejects Another Acquisition Offer From Cycle, Affirms Confidence in Business
Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was being proposed for the treatment of gastroparesis.
Vanda Rejects Another Acquisition Offer From Cycle, Affirms Confidence in Business Read More »
